PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.
P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.
Minoxidil can cause heart palpitations, and users experiencing this should consider reducing the dosage or switching to alternatives like rosemary oil. It's advised to consult a doctor if side effects occur.
The conversation discusses hair loss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hair loss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hair follicles to androgens.
A 30-year-old man shared his experience with finasteride, taking 1mg every other day, which led to sexual side effects and other issues, prompting him to stop the treatment despite initial hair improvement. He previously tried natural methods and minoxidil without much success and is now considering a buzzcut.
Finasteride and dutasteride may not significantly impact meibomian gland function since these glands do not rely on DHT. Some users report dry eyes and other side effects from finasteride, but these may be influenced by other factors or medications.
Using 0.025% tretinoin may enhance minoxidil's effects for hair loss. Users suggest starting with 0.025% and gradually increasing the concentration, and discuss combining treatments like microneedling.
A 28-year-old male noticed hair thinning and is considering treatments like minoxidil and finasteride but is concerned about finasteride's potential effects on epilepsy. He has tried microneedling, tretinoin, and minoxidil with slight improvement.
Finasteride may cause insomnia, and ashwagandha is suggested to help with sleep issues without significantly affecting testosterone or DHT levels. Users discuss personal experiences with sleep disturbances and suggest consulting a doctor if side effects persist.
The conversation is about using pyrilutamide and RU58841 as topical solutions to prevent hair loss. Pyrilutamide is considered safer but less potent than RU58841, which some users find effective despite potential side effects like heart palpitations.
The conversation is about the lack of improvement in hair loss after using Pyrilutamide for 14 weeks, with the original poster unable to use Finasteride due to depression. Replies suggest that Pyrilutamide, like RU58841, may not work for everyone, and a more potent drug is being developed by Kintor.
The user experienced heart palpitations after increasing their oral minoxidil dosage and starting a new topical minoxidil formulation. They wish to stop oral minoxidil for heart health and continue with topical minoxidil.
The user is concerned about using dutasteride for potential hair loss, fearing it might accelerate balding if not effective. They are unsure about the doctor's diagnosis and are considering starting with finasteride instead.
The user started using finasteride, minoxidil, and biotin for hair loss and believes they are a hyper responder, noticing significant changes in hair thickness. They regret not starting earlier and mention using oral minoxidil.
KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.
A Dutasteride Simulator predicts serum dutasteride, serum DHT, and scalp DHT levels using models from research papers. It simulates various dosing schedules to determine steady-state effects and visualizes outcomes, including hair growth-related scalp DHT suppression.
Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.
The user is experiencing scalp irritation from a compounded treatment of finasteride, minoxidil, and tretinoin. They are considering switching to a non-alcohol, propylene glycol-free formula with a lower tretinoin percentage to reduce irritation.
The user saw some improvement with topical minoxidil over 6-7 months and recently switched to oral minoxidil and finasteride, experiencing mild side effects from finasteride. They are concerned about losing gains from topical minoxidil and are seeking advice on whether to continue with the new regimen.
The user noticed a slight loss of progress after switching to Milpharm finasteride 1mg and is considering switching to Accord finasteride. They seek advice on whether to continue with Milpharm or switch brands.
The conversation discusses concerns about the effectiveness of RU58841 due to high temperatures during delivery. A user reassures that the heat will not affect its efficacy.
Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
Higher doses of dutasteride for hair loss are debated, with some users suggesting they are unnecessary and potentially unsafe. The original poster uses a combination of dutasteride, minoxidil, and RU58841 for hair regrowth, despite concerns about high dosages.
The user switched from finasteride to 2.5 mg dutasteride daily and added 1% pyrilutamide to address persistent scalp itch, but the itch remains. They also use 2% ketoconazole and 2.5% selenium sulfide shampoo for temporary relief.
The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.
Upcoming hair loss treatments for those who can't tolerate DHT blockers, focusing on Minoxidil, microneedling, and ketoconazole. Promising treatments include GT20029, PP405, KX-826, and RU58841, though RU58841 may not be safe.
The conversation discusses whether drinking coffee affects the hair growth benefits of Minoxidil, with one user mentioning that Minoxidil's vasodilation is stronger than caffeine's vasoconstriction, and another sharing personal experience of better hair growth after quitting caffeine while on Minoxidil.
Adding non-prescription topicals like alfatradiol and Zix to a standard fin/min/niz regimen may help with scalp inflammation and shedding, but their long-term effectiveness varies. Zix is recommended for reducing scalp inflammation and enhancing the effectiveness of other treatments.